Meeting
2022 ASCO Annual Meeting
Postoperative ctDNA in indicating the recurrence risk and monitoring the effect of adjuvant therapy in surgical non–small cell lung cancers.
Authors
Xiaoru Tian
Xuanwu Hospital Captical Medical University, Beijing, China
Xiaoru Tian , Ruotian Wang , Kun Qian , Yuanbo Li , Tengteng Wang , Lei Liu , Baodong Liu , Lei Su , Peilong Zhang , Xin Zhao , Kai Wang , Yuanyuan Xiong , Yi Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8533)
DOI
10.1200/JCO.2022.40.16_suppl.8533
Abstract #
8533
Poster Bd #
160
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Impact of postoperative integrated genomic and epigenomic signatures of circulating tumor DNA (ctDNA) on recurrence in resected colorectal cancer: Initial report of a prospective ctDNA monitoring study COSMOS-CRC-01.
First Author: Yuichiro Tsukada
Poster
2021 ASCO Annual Meeting
Minimal residual disease (MRD) in patients with resected stage I NSCLC: Results of the prospective adjuvant IFCT-0703 trial.
First Author: Damien Vasseur
Poster
2014 ASCO Annual Meeting
Circulating tumor DNA (ctDNA) as a marker of recurrence risk in stage II colon cancer (CC).
First Author: Jeanne Tie
Poster
2024 ASCO Annual Meeting
Prediction of recurrence in stage I EGFR mutation-positive NSCLC: Combination of CT appearance and selected co-occurring gene alterations by machine learning.
First Author: Akiko Tateishi